Published: April 17, 2025
Source: Journal of Clinical Oncology, ASCO 2025 Guidelines
In a landmark update, the American Society of Clinical Oncology (ASCO) has released new guidelines on sentinel lymph node biopsy (SLNB) for patients with early-stage breast cancer, published in the Journal of Clinical Oncology in 2025. These evidence-based recommendations, developed by experts including Dr. Ko Un Park and Dr. Mark Somerfield, are poised to transform treatment approaches, reduce unnecessary procedures, and improve patient outcomes. Backed by extensive research, including 11 randomized clinical trials, 8 meta-analyses, and a prospective cohort study spanning 2016 to 2024, this guideline update offers six key recommendations for stages I and II breast cancer. Here’s a detailed breakdown of the guidelines, their implications, and what they mean for patients and healthcare providers.
Key Recommendations of the ASCO 2025 Guidelines
The ASCO guidelines focus on optimizing the use of SLNB, a procedure that examines lymph nodes to determine if cancer has spread, while minimizing invasive interventions like axillary lymph node dissection (ALND). Below are the six major recommendations and their supporting evidence:
1. Skipping SLNB in Low-Risk Cases
For postmenopausal women aged 50 or older with small, low-risk breast cancers—tumors 2 centimeters or less, hormone receptor-positive, and HER2-negative—SLNB may not be necessary if an ultrasound shows no lymph node abnormalities. For patients 65 and older, radiation therapy may also be omitted in some cases.
- Evidence: Trials like SOUND and INSEMA demonstrated no difference in survival when SLNB was skipped in these patients, with axillary recurrence rates as low as 1–1.7%. This approach reduces complications like lymphedema and improves quality of life.
2. SLNB Should Not Alter Other Treatments
Skipping SLNB should not impact decisions about radiation therapy or systemic therapy, including genomic tests like the 21-gene recurrence score. The guidelines emphasize maintaining standard care protocols.
- Evidence: The INSEMA trial required whole-breast radiation, while SOUND allowed partial breast radiation, and both showed strong outcomes, reinforcing the safety of skipping SLNB without compromising treatment efficacy.
3. Avoiding ALND in Breast-Conserving Surgery
For patients with one or two positive sentinel lymph nodes undergoing breast-conserving surgery and radiation, ALND is not recommended. This reduces the risk of complications like lymphedema, which can significantly affect quality of life.
- Evidence: The ACOSOG Z0011 and SENOMAC trials found that ALND does not improve survival but increases lymphedema risk, with rates as high as 24.5% compared to 11.9% with radiation alone.
4. ALND in Mastectomy Cases
For patients undergoing mastectomy with one or two positive sentinel nodes, ALND can be skipped if postmastectomy radiation with regional nodal irradiation is planned. However, ALND is recommended if radiation is not planned or if three or more nodes are positive.
- Evidence: The AMAROS and SENOMAC trials showed that radiation provides comparable outcomes to ALND with fewer side effects, supporting less invasive approaches.
5. No ALND for Negative Lymph Nodes
If no lymph node metastases are found during SLNB, ALND is unnecessary. This recommendation aims to avoid unwarranted invasive procedures.
- Evidence: The NSABP B-32 trial confirmed that ALND in these cases does not improve survival and only increases lymphedema risk.
6. Special Cases and Exceptions
SLNB may be considered for specific scenarios, including:
- Multicentric tumors
- Male breast cancer
- Pregnancy
- Obesity
- Larger tumors
- Ductal carcinoma in situ (DCIS) with mastectomy
However, SLNB is not routine for DCIS with breast-conserving surgery or for evaluating internal mammary nodes. For inflammatory breast cancer or confirmed lymph node involvement, ALND remains the standard treatment.
- Note: These recommendations are based on limited data, so shared decision-making between patients and providers is critical.
Addressing Health Equity
A critical focus of the ASCO guidelines is health equity, particularly for Black patients, who have historically faced disparities in breast cancer care. Studies show Black patients have higher rates of ALND and lymphedema (12% vs. 8% for White patients). ASCO emphasizes the need for:
- Improved access to care
- Better patient-provider communication
- Targeted interventions to close these gaps
By reducing unnecessary procedures, the guidelines aim to ensure equitable treatment and outcomes across all patient populations.
Cost Savings and Quality of Life
The guidelines highlight significant cost-saving potential by skipping SLNB or ALND in appropriate cases. Avoiding these procedures reduces complications like lymphedema, which can lead to long-term physical and financial burdens. ASCO encourages healthcare providers to discuss financial options with patients to alleviate economic stress and improve access to care.
- Evidence: Studies cited in the guidelines demonstrate that less invasive approaches not only save costs but also enhance patients’ quality of life by minimizing side effects.
Why These Guidelines Matter
The ASCO 2025 guidelines represent a shift toward personalized, less invasive breast cancer care. By leveraging data from high-quality clinical trials, the recommendations aim to:
- Reduce unnecessary procedures like SLNB and ALND
- Minimize complications such as lymphedema
- Lower healthcare costs while maintaining survival rates
- Promote health equity by addressing disparities in care
Endorsed by the American Society for Radiation Oncology, these guidelines are reshaping clinical practice and offering hope to thousands of patients with early-stage breast cancer.
What’s Next?
Patients and healthcare providers should engage in shared decision-making to determine the best course of action based on individual risk factors and preferences. For those interested in learning more, visit OncologyTube.com for in-depth resources on breast cancer care and the latest oncology updates.
Stay informed, and join the conversation about advancing breast cancer treatment. Subscribe to OncologyTube for more insights into groundbreaking guidelines and innovations in oncology.
Published: April 17, 2025
Source: Journal of Clinical Oncology, ASCO 2025 Guidelines
Tags: Breast Cancer, Sentinel Lymph Node Biopsy, ASCO Guidelines, Health Equity, Oncology
Link To Full ASCO Guideline: https://ascopubs.org/doi/full/10.1200/JCO-25-00099